The same event can reach both: a study opening is one line under its program in the brief, and one study’s change in the alerts.
The registry lists 4,850 studies for Asthma across more than 10 countries. 604 are recruiting or about to start. 4,241 of them are mainly about Asthma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18. Counting its 2 narrower conditions too, such as Asthma, Exercise-Induced: 4,899 studies, 606 open.
ClinicalTrials.gov finds 5,318 studies for Asthma.How that becomes 4,846 hereChecked on ClinicalTrials.gov . The studies here are updated every night.
This page counts the studies the registry files under Asthma, and those it files under no condition that list Asthmathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count
5,318Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−250List Asthma as a condition, but the registry did not file them under itMost often written as “Asthma in Children” (53), “Allergic Asthma” (33), and “Severe Eosinophilic Asthma” (15). The registry filed them under other conditions only, most often Pulmonary Eosinophilia (40) and Rhinitis, Allergic (37).
−173Match it another way112 name it in the title, 21 in a keyword, and 40 by a synonym or other text the search reads.
4,846The count on this page372 of them list Asthma in their own words; the registry filed them under no condition.
Add Asthma to watchlistPro · free during the betaEvery Monday by email · turn it off any time
Every program with a company-led study here in the last two years, whatever its size: 73 programs from 46 companies, 71 with this as their studies’ main aim; 17 with a live phase 3 study; 17 primary completions in the next 12 months. Compare AstraZeneca, Chiesi Farmaceutici and GlaxoSmithKline here →
Comparator & background therapies
What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.
“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.
studied with Albuterolstudied with Mannitolstudied with Budesonide · own drug+1 more
The 5 in phase 3 with the nearest primary completion, of 73 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.
Primary completion in the next 12 months (17)
Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.
Dec 2026 est.rademikibart· Connect Biopharm LLC · Phase 2main aimNCT07705737 Rademikibart IV for Acute Asthma and COPD Exacerbation — primary endpoint: Change from baseline in post-BD FEV1 · 40 enrolled
Dec 2026 est.ENV-294· Enveda Therapeutics · Phase 2main aimNCT07301255 ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults — primary endpoint: Incidence and Severity of Adverse Events · 50 enrolled
23 Dec 2026 est.benralizumab· AstraZeneca · Phase 3main aimNCT05692180 A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma — primary endpoint: Time to first asthma exacerbation · 94 enrolled
Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.
What is being tested here
Drugs under test in Asthma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
213studies finish main data collection within a year16 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger. 145 (35%) take children under 18. 4 (1%) are for women only and 0 (0%) for men only; 105 (25%) take healthy volunteers.
Across all 4,850 studies, recruiting or not: 61% stop at 75 or younger and 50% at 65; 42% take children; 1% are for women only and 2% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Asthma studies take
Of 205 phase 3 interventional studies under Asthma, half reached primary completion within 27 months of starting, counting those still running.
Start to primary completion
Every sponsor
Industry
Non-industry
Phase 1
6 mo3–14 · 200 studies
6 mo3–12 · 173 studies
—
Phase 2
20 mo12–41 · 199 studies
16 mo10–23 · 137 studies
46 mo28–62 · 62 studies
Phase 2/3
28 mo12–59 · 14 studies
—
—
Phase 3
27 mo14–42 · 205 studies
25 mo14–41 · 173 studies
35 mo18–54 · 32 studies
Phase 4
24 mo11–37 · 156 studies
21 mo9–33 · 66 studies
27 mo12–51 · 90 studies
Interventional, no phase
23 mo10–48 · 650 studies
12 mo5–24 · 50 studies
24 mo11–50 · 600 studies
Observational
36 mo18–82 · 456 studies
27 mo17–58 · 90 studies
38 mo18–97 · 366 studies
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 20, 2026.